The Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data

Basit Öğe Kaydı
dc.authoridAlkan, Sevil / 0000-0003-1944-2477
dc.contributor.authorGürbüz, Yunus
dc.contributor.authorKocagül-Çelikbaş, Aysel
dc.contributor.authorÖztoprak, Nefise
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorBatırel, Ayşe
dc.contributor.authorHabiloğlu, Arif Doğan
dc.contributor.authorAktuğ-Demir, Nazlım
dc.contributor.authorAlkan, Sevil
dc.date.accessioned2025-01-27T21:19:51Z
dc.date.available2025-01-27T21:19:51Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.descriptionThis work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.
dc.description.abstractObjective: This study aimed to demonstrate the real-life efficacy and safety of glecaprevir / pibrentasvir in the treatment of chronic hepatitis C, as well as to identify the problems caused by the COVID-19 pandemic in the follow-up and treatment of patients. Materials and Methods: The study was conducted retrospectively with the participation of researchers from universities or training and research hospitals. It included patients with chronic hepatitis C who were over 18 years of age, treatment-na & iuml;ve or treatment-experienced, had detectable HCV RNA and were receiving glecaprevir/pibrentasvir treatment Results: Only 188 of the 385 patients who participated in the study came to the follow-up visit 12 weeks after treatment, and all of them had a sustained virological response. It was thought that a significant portion of the 177 patients who did not come to the follow-up visit at 12 weeks after treatment refrained from coming to the hospital due to the COVID-19 pandemic. None of the patients who attended the follow-up visits required treatment discontinuation due to adverse events. Conclusion: Glecaprevir/pibrentasvir is a highly effective and relatively safe drug in the treatment of chronic hepatitis C. The COVID-19 pandemic has negatively affected the follow-up and treatment processes of patients. New measures are needed for the follow-up and treatment of patients with chronic hepatitis C during pandemics.
dc.identifier.doi10.36519/idcm.2024.344
dc.identifier.endpage224
dc.identifier.issn2667-646X
dc.identifier.issue3
dc.identifier.pmid39399749
dc.identifier.scopus2-s2.0-85211167386
dc.identifier.scopusqualityN/A
dc.identifier.startpage216
dc.identifier.trdizinid1280203
dc.identifier.urihttps://doi.org/10.36519/idcm.2024.344
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1280203
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28753
dc.identifier.volume6
dc.identifier.wosWOS:001342409100005
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherKLİMİK (Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği)
dc.relation.ispartofInfectious Diseases and Clinical Microbiology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectglecaprevir
dc.subjectpibrentasvir
dc.subjectchronic hepatitis C
dc.subjectCOVID-19
dc.subjectmulticenter study
dc.titleThe Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Sevil Alkan_Makale.pdf
Boyut:
178.87 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu